Aethlon Medical Announces Investigation Of The Hemopurifier For Use In Organ Transplantation
Portfolio Pulse from Happy Mohamed
Aethlon Medical (NASDAQ:AEMD) is investigating the use of its Hemopurifier in the organ transplant market, aiming to confirm its ability to remove harmful viruses and exosomes from harvested organs. The global transplantation market is projected to reach $33.7 billion by 2032, with an 8.36% CAGR from 2023 to 2032.
June 21, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aethlon Medical's investigation of Hemopurifier in the organ transplant market could potentially expand its applications and revenue streams. The global transplantation market is projected to grow significantly.
Aethlon Medical's investigation of Hemopurifier in the organ transplant market could potentially expand its applications beyond cancer and COVID-19 treatments. This would open up a new revenue stream for the company, tapping into the growing transplantation market, which is projected to reach $33.7 billion by 2032 with an 8.36% CAGR from 2023 to 2032. If successful, this could positively impact AEMD's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100